Heidelberg Pharma AG
Clinical-stage biopharma developing Amanitin-based ADCs for targeted cancer therapies.
HPHA | F
Overview
Corporate Details
- ISIN(s):
- DE000A11QVV0
- LEI:
- 391200E09XYBYITR1W32
- Country:
- Germany
- Address:
- Gregor-Mendel-Str. 22, 68526 Ladenburg
- Sector:
- Manufacturing
Description
Heidelberg Pharma AG is a clinical-stage biopharmaceutical company specializing in the development of targeted cancer therapies. The company's core focus is its proprietary Antibody-Drug Conjugate (ADC) technology platform, which utilizes the toxin Amanitin. This platform, known as Antibody Targeted Amanitin Conjugates (ATACs®), is designed to deliver the highly potent Amanitin payload directly to tumor cells. Heidelberg Pharma is the first company to advance Amanitin into clinical development for cancer treatment. Its lead candidate, HDP-101, is in clinical trials for patients with multiple myeloma. The company leverages its ADC expertise to create novel medicines for oncology.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2017-11-10 14:38 |
DGAP-DD: Heidelberg Pharma AG english
|
English | 7.1 KB | ||
| 2017-11-03 12:41 |
Heidelberg Pharma AG plans capital measure to fund its ATAC development programs
|
English | 23.7 KB | ||
| 2017-10-26 14:14 | English | 12.5 KB | |||
| 2017-10-26 14:05 | English | 12.5 KB | |||
| 2017-10-26 13:59 | English | 12.9 KB | |||
| 2017-10-26 10:53 |
Heidelberg Pharma AG: Partner RedHill Announces Orphan Drug Designation for MES…
|
English | 8.6 KB | ||
| 2017-10-19 18:15 |
WILEX AG successfully completes change of name to Heidelberg Pharma AG
|
English | 9.2 KB | ||
| 2017-10-11 00:00 |
Q3 statement / Q3 financial report 2016/2017
|
German | 119.7 KB | ||
| 2017-10-09 19:13 |
WILEX AG: Interim management statement for the first nine months of 2017
|
English | 30.9 KB | ||
| 2017-10-09 18:49 |
WILEX AG Announces Adjustment of Guidance
|
English | 10.0 KB | ||
| 2017-10-09 00:00 |
Datum:09.10.2017
|
German | 136.0 KB | ||
| 2017-09-26 13:12 |
WILEX AG: Subsidiary Heidelberg Pharma becomes Runner Up in the Category Best N…
|
English | 9.3 KB | ||
| 2017-09-20 07:13 |
WILEX AG: Subsidiary Heidelberg Pharma to Present the Proprietary ATAC Technolo…
|
English | 10.3 KB | ||
| 2017-07-13 07:08 |
WILEX AG reports first half 2017 results
|
English | 27.7 KB | ||
| 2017-07-13 00:00 |
Half-yearly financial report 2016/2017
|
German | 594.6 KB |
Automate Your Workflow. Get a real-time feed of all Heidelberg Pharma AG filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Heidelberg Pharma AG
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Heidelberg Pharma AG via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-01-31 | Pahl, Prof. Dr. Andreas | Board | Other | None | N/A |
| 2023-12-18 | Pahl, Prof. Dr. Andreas | Board | Buy | None | 10,130.00 EUR |
| 2022-10-13 | 4H invest GmbH | Close relation | Other | None | 993,666.24 EUR |
| 2022-10-13 | Bohlini invest GmbH | Close relation | Other | None | 964,061.56 EUR |
| 2022-10-13 | MH-LT-Investments GmbH | Close relation | Other | None | 506,241.96 EUR |
| 2022-10-13 | Schneiders, Michael | Board | Buy | None | 13,088.40 EUR |
| 2022-10-13 | Schneiders, Michael | Board | Buy | None | 4,895.60 EUR |
| 2022-09-07 | Plate, Achim | Board | Buy | None | 30,869.92 EUR |
| 2022-09-06 | Kudlek, Dr. Birgit | Supervisory board | Other | None | 7,496.16 EUR |
| 2022-03-22 | 4H invest GmbH | Close relation | Other | None | N/A |
Peer Companies
